What’s New in Neuromodulation? News to Know Before NANS 2026

The North American Neuromodulation Society (NANS) is once again bringing together the leading clinicians, researchers and manufacturers to Caesar’s Palace in Las Vegas for the NANS 2026 Annual Meeting, to be held January 22-25.

SmartTRAK will be represented at NANS 2026 by Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, and Thom Clark, Sr Director, Enterprise Strategy & Solutions. If you would like to meet with us, please reach out to anne.staylor@smarttrak.com, or just click the button below.

To get you up to speed before the meeting, SmartTRAK has put together highlights of recent neuromodulation news. The following is just a small sampling of recent neuromodulation-related news and updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts at SmartTRAK.

Market

• SmartTRAK estimates full-year US DBS Market revenues for 2025 will be up approximately +11% YoY, which is in line w/ SmartTRAK’s US DBS Market Overview projection of +10.8% YoY growth. SmartTRAK Financial Dashboard
• Based on SCS revenue YTD 2025, the US SCS Market is growing +2.9% YoY, which is in line w/ SmartTRAK’s original SCS Market Overview projection of +3.0% YoY growth. SmartTRAK Financial Dashboard
• Payer scrutiny and preauths will continue to place downward pressure on SCS, particularly because of CMS’ WISeR model set to launch 1/1/26. WISeR is piloting the preauth of SCS perm implants (NCD 160.7) for standard Medicare pts in 6 states. SmartTRAK Q325 Neuromodulation Recap
• GMED sees an opportunity to grow the NVRO business through surgeon conversion and competitive rep recruitment and views SCS as a continuum of spine care rather than as a standalone therapy. SmartTRAK Q325 Neuromodulation Market Recap
• A large unmet need exists in epilepsy, as one-third of patients (36%) do not benefit from drugs. This results in a global DRE prevalence of approximately 10MM people, w/ 1MM in the US, 2MM in Europe and 7MM in the ROW. LIVN 2025 Investor Day Presentation 
• Bioventus believes the acquisition of Nalu by BSX validates the potential of the PNS mkt. In the US, the PNS mkt is ~$200MM and is estimated to grow above 20% annually, exceeding $500MM by 2029. Bioventus Q325 Earnings Presentation  

Clinical/Regulatory/New Products

• NPCE announced it filed a FDA PMA-S application to expand the RNS System’s labeled indication to include pts w/ medication-resistant idiopathic generalized epilepsy w/ generalized tonic-clonic seizures. The PMA-S was supported by preliminary results of the NAUTILUS trial.
• The FDA approved BSX’ PMA supplement for the WaveWriter SCS MRI Safety Guidelines to add the MDT Specify SureScan MRI Leads to the list of compatible w/ the BSX M8 Adaptor and to label WaveWriter Alpha SCS Mixed System using MDT’s Specify SureScan leads as MRI scan eligible.
• Saluda Medical announced its next-gen EVA Sensing Technology has received CE certification in Europe, w/ recognition of this approval in Australia. This follows FDA approval of EVA in December 2024. A limited market release will begin in Q126 w/ full market release later in 2026.
• Curonix announced the expansion of its Freedom Peripheral Nerve Stimulator System w/ the launch of a new wearable accessory that targets chronic pain in the head, neck, shoulder and upper torso regions.

Patents

• MDT’s US Patent Application "Method And Apparatus For Planning Placement Of An Implant" was published re analyzing image data to ID anatomical landmarks/brain network connections to plan/position a DBS implant in an optimal position for therapy (e.g., for epilepsy). 20250352268
• BIOTRONIK's US Patent Application "System And Method For Feedback Control Of Neural Stimulation" was published describing a closed-loop control system configured to update an amplitude of the therapeutic electric pulse based on ECAP signals. 20250375614
• Nevro's US Patent Application "Sensory Threshold And/or Adaptation For Neurological Therapy Screening And /or Parameter Selection, And Associated Systems And Methods" was published re using sensory threshold and/or adaptation for screening/parameter selection. 20260007892
• BSX' US Patent Application "Techniques For Spinal Cord Stimulation Targeting Using Dermatome Assessment" was published, describing methods and systems for determining an optimal stimulation location in an electrode array of a spinal cord stimulator. 20260007891
• Advanced Neuromodulation Systems was granted US Patent "Systems And Methods For Providing Digital Health Services" re systems/methods for conducting virtual or remote sessions between pts and clinicians using media content captured as the pt performs one or more tasks. 12515057

Deals/Financing

• BSX announced it will acquire the remaining equity of Nalu Medical w/ an upfront cash payment of approximately $533MM. BSX, which first invested in Nalu in 2017, expects the deal to close in the first half of 2026. Nalu is projected to generate over $60MM in sales this year.
• INBRAIN Neuroelectronics announced a partnership w/ Microsoft to combine its precision graphene neural technology w/ Microsoft’s Azure AI infrastructure, aiming to advance real-time precision neurology and BCI therapeutics for conditions such as Parkinson’s and epilepsy.
• Spiro Medical, a neuro-respiratory startup based in Irvine, CA, received $67MM in Series A funding led by Andera Partners, a leading EU private equity firm, to develop a 1^st-of-its kind pulmonary neuromodulation system for the tx of asthma and other chronic airway diseases.
• SetPoint Medical recently raised $140MM in private financing and plans to use the proceeds to support commercialization of the SetPoint System for pts w/ moderate-to-severe rheumatoid arthritis and to advance the pipeline in other autoimmune conditions.
• BSX announced it has entered into a definitive agreement to acquire Valencia Technologies and its eCoin System, an implantable tibial nerve stimulation devices for the tx of urinary incontinence, a common sx of OAB that affects almost 30MM adults ages 40+ in the US.
• Precision Neuroscience announced a strategic partnership w/ MDT leveraging Precision’s BCI technology and MDT’s Neuroscience portfolio to co-develop an integrated solution that combines Precision’s Layer 7 interface w/ MDT’s StealthStation surgical navigation system.

• Pope et al. retrospectively analyzed real-world SCS utilization in 493 pts implanted w/ a remote monitoring-capable SCS system. After 1 yr, 95.1% remained implanted, w/ 96.8% of those actively using the tx. Only 0.9% were "virtual explants" (prolonged inactivity). Neuromodulation
• Eldabe et al.’s network meta-analysis (NMA) of 16 trials (1,887 pts) shows all SCS types beat CMM for chronic pain over 24 mos. Pain scores dropped by 2.37-5.55 points. Evidence certainty is low, but results show significant pain relief and higher responder rates vs CMM. RAPM
• In a real-world study of 78 CRPS pts (42 LL, 30 UL), preliminary results showed FAST sub-perception SCS w/ surround inhibition reduced NRS pain by 3.5 and 4.2 points for pts w/ UL and LL, respectively, at 12 mos, w/ substantial improvements in disability and QofL. Neuromodulation
• SPR Therapeutics announced that ASPN’s evidence-based PNS consensus guidelines were published in the Journal of Pain Research. The guidelines highlight evidence supporting the use of PNS for chronic pain and a wide range of indications and advocate for broader payer coverage.
• The RESET RCT (N=230) showed 60-day PNS significantly outperformed standard intvnl mgmt (control) in pts w/ refractory CLBP. At 30 days, 55% of the PNS group reported ≥ 50% pain relief vs 26% in the control (P<.001) and PNS saw improvements in ODI and QoL through 6 mos. Pain Med